Further, the rising number of regulatory approvals for targeted therapies in the treatment of cancer is another factor contributing to the segmental growth. By product type, the over-the-counter (OTC) drugs segment is expected to be the fastest CAGR growing in the upcoming years. Nowadays, consumers are widely adopting OTC drugs to resolve insignificant ailments and track their complete well-being, because of their convenience and reasonable compared to prescription drugs. Also, rising emphasis on proactive health management is resulting in a greater demand for OTC products, which is coupled with self-care and preventive measures. The worldwide drugs market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. The increasing prevalence of cardiovascular diseases, cancer, diabetes, and neurological disorders is fueling the demand for innovative treatments and personalized medicine.
- Rising prevalence of chronic diseases and the growing need for effective therapies support market expansion.
- With 30 street dealers, this would total about two sales per dealer per day, assuming that individuals sell only about half the days of the year.
- Generic drugs offer a cost-effective alteative while maintaining the same quality and therapeutic efficacy as the brand-name drug.
- The phenomenon of unemployment suggests excess supply of workers (at a given wage) within the labor market.
- Most jurisdictions prohibit trade, except under license, of many types of drugs through the use of drug prohibition laws.
How Many Segments Are Included In The Drug Market, And What Are They?
Thus, the rebound in the number of hospital visits by patients’ post-pandemic, coupled with the high consumption of prescription drugs in homecare settings, boosted the global prescription drugs market growth. Asia Pacific is expected to be the fastest-growing region in the projected timeframe, as a rising number of aging populations with chronic conditions like hypertension, diabetes, and dementia are significantly driving the growth of the drugs market. Although novel advanced technologies in drug delivery, including nanotechnology, microencapsulation, and 3D printing, are optimizing drug efficacy and bioavailability, which leads to the enhanced demand for drugs.
Drug Repositioning: One Molecule Two Indications Triple The Profits
This launch follows FDA approval through Lupin’s alliance partner, ForDoz Pharma Corporation, and is part of Lupin’s strategy to expand its oncology portfolio. Adults (ages 15-64) accounted for the largest share of 64.83% of the pharmaceutical market in 2024. The rising use of prescription drugs in this demographic, particularly for conditions like hypertension and diabetes, is expected to continue driving market growth. The pediatric and adolescent segment is also anticipated to grow significantly due to the increasing number of pediatric drug approvals and the rise in childhood conditions requiring medical treatment. However, the over-the-counter (OTC) segment is expected to grow the fastest, driven by rising prescription drug costs and the shift toward self-medication.
The national overdose growth rate, remarkably constant over the period and roughly doubling every eight years, is apparently impervious to shifts in policy interventions. Even the emergence and decline of specific drugs has little effect; deadly as fentanyl is, statistically, it looks merely like an extension of what was even in 2015 a 35-year trend. Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential. They are one of the main profit-generating activities of organised crime and are estimated to represent around one-fifth of global crime proceeds.
Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Office On Drugs And Crime
The web-based Drug market patterns and trends contains the latest analysis of global, regional and subregional estimates of and trends in drug demand and supply in a user-friendly, interactive format supported by graphs, infographics and maps. The rising demand for oncology drugs such as keytruda, revlimid and opdivo for the treatment of chronic diseases such as melanoma, multiple myeloma, and lung cancer, among others, is further driving the segmental growth in the market. The other prescription drugs segment held a dominant share in 2022, owing to the rise in the adoption of these drugs for pain management and diabetes treatment among the population. Moreover, the increase in the number of drugs prescribed by healthcare professionals for several disease treatments augments the segment share. Thus, the growing number of approvals of generic drugs drives the US pharmaceutical market share and demand for generic segment. Pharmaceutical is a broad segment that consolidates a group of chemicals classified based on their pharmacological effect and therapeutic use.
Further Reports
- Although it has been hard to pin down the magnitude of the price responsiveness (as summarized by the price elasticity of demand), there is general empirical support for the proposition that drug demand curves slope downward.
- The first few weeks were met with extremely high demand, most shops being out of stock after operating for only four days.
- The web-based Drug market patterns and trends module contains the latest analysis of global, regional and subregional estimates of and trends in drug demand and supply in a user-friendly, interactive format supported by graphs, infographics and maps.
- With a significant 20% share in the global supply, India manufactures around 60,000 different generic brands across 60 therapeutic categories.
Figure 3 shows thelevel of competition among specialty drugs in small molecule drug andbiological product markets, and both curves show an increase in theshare of single-manufacturer products. In total, there were 347specialty small molecule drugs in 2017 (19 percent of all small moleculedrugs), which increased to 434 by 2022 (24 percent of all small moleculedrugs). In 2022, 273 specialty small molecule drugs (63 percent) hadonly one manufacturer, 51 specialty small molecule drugs had 2-3manufacturers (12 percent), and 26 specialty small molecule drugs (6percent) had 4-5 manufacturers. The only competition category thatchanged noticeably, as a percentage share of the total, over the sampleperiod was the number of specialty small molecule drugs with 6+manufacturers, which increased from 49 drugs in 2017 to 84 drugs in2022, an increase of 71.4 percent. The children & adolescent segment is expected to show a significant growth rate over the forecast period.
A Brief History: From Policy Catalyst To Global Juggernaut
The pharmaceutical market in Brazil is fueled by high prevalence of chronic diseases, government efforts to improve healthcare outcomes, and investments in local production. Increasing access to healthcare services and the availability of effective therapies for conditions such as hypertension and diabetes support market expansion. Hospital pharmacies lead distribution, with retail pharmacies providing greater accessibility for outpatient care.
Pharmaceutical Market Size And Forecast 2025 To 2034
Although there has been a rise in the number of drugs introduced, including those receiving over-the-counter status in the U.S., healthcare professionals are emphasizing treating patients with these drugs to a comparatively larger extent. The increasing incidence of rare diseases is expected to propel the growth of the pharmaceutical drug market going forward. A rare disease refers to a low-prevalence health issue that, in comparison to other common diseases in the population, only affects a tiny number of people. Approximately 80% of these diseases have a recognized genetic basis, with 1 in 17 people expected to be affected by a rare disease at some stage in their life.
Global Prescription Drugs Market Snapshot & Highlights
North America pharmaceutical market holds a leading position in 2024, accounting for 41.87% of the global share. The region’s dominance is driven by high healthcare expenditure, strong regulatory frameworks, and advancements in biologics and personalized medicine. The U.S. leads the region, benefiting from significant R&D investments, early drug approvals, and a robust pipeline of innovative therapies. Hospital pharmacies dominate distribution, while retail and online pharmacies continue to expand their presence. In the U.S., generic pharmaceutical companies are responsible for manufacturing the medicines used in 9 out of 10 prescriptions that are dispensed.
In addition, small molecules often exhibit better membrane penetration, allowing for targeting intracellular pathways, further solidifying their position in drug development pipelines. We mention just three ways in which their data are inconsistent with other data on drug markets. The best estimate of total sales volume in the cocaine market is $30 billion for 1995 (Office of National Drug Control Policy, 2001). We assume, conservatively, that one-quarter of that was accounted for by crack, giving total crack revenues of $7.5 billion.
REPORT COVERAGE
AbbVie is another US pharmaceutical market participant that has made a great impression worldwide, with the pharmaceutical segment generating a record US$ 55 billion in 2021, driven especially by its longstanding top-seller brand Humira. Despite the influence of several emerging countries, the US has captured a dominant share of the pharmaceutical market globally. Most advanced US pharmaceutical market products are easily accessible to American consumers, albeit at a cost. There are several reasons for this region’s supremacy, including improvements in clinical trials and medication production in the US and Canada.
